Research news

Research carried out at IBEC has opened the way to new applications to control the activation of neurons and other working parts of cells.

The dream of precisely and remotely controlling every aspect of the cell’s inner workings in tissue offers the promise of uncovering the molecular mechanisms of complex cellular processes, which in turn can lead to leaps in our understanding of what happens when things go wrong – for example, how and when neurodegenerative diseases can develop.

A study by researchers from IBEC, ISGlobal and the University of Barcelona published in Nanomedicine opens the door to improved treatment of malaria with heparin.

Heparin (left) has been shown to have antimalarial activity and specific binding affinity for red blood cells infected with Plasmodium falciparum, versus non-infected blood cells. The study explores whether these properties could be exploited in a strategy based on the targeted delivery of antimalarial agents.

Researchers at IBEC and the UB have discovered a new factor that participates in the lack of symptoms in the early stages of Alzheimer’s disease – which is one handicap that makes the disease so hard to diagnose.

In the paper published in Molecular Neurobiology, the researchers reveal that our nervous system’s naturally protective response to the onset of Alzheimer’s may contribute to the fact that patients do not suffer memory loss until the disease has progressed further.

Researchers from IBEC and the University de Barcelona (UB), in collaboration with the Institute of Marseille Luminy, University of the Mediterranean in France and the Cincinnati Children’s Hospital, USA, have identified for the first time a new molecular mechanism regulating the migration of Cajal-Retzius cells in the early stages of development of the cerebral cortex, the outermost layer of the brain.

A study by IBEC researchers reveals in Nature Materials how mammary cells detect tissue stiffening, which is key to the development of breast cancer

Achieving control of tissue stiffness could open a new avenue to treat tumours like those in the breast

Abnormally rigid tissues are also found in several other types of cancer, so the newly revealed mechanism could be a key aspect behind the onset of various diseases

A new acoustic method for better diagnosis in patients with diaphragmatic paralysis

A PLOS ONE article by researchers from the joint unit IBEC, the Fundació Institut Germans Trias i Pujol (IGTP) and the Pneumology Service at Germans Trias i Pujol University Hospital describes the acoustic analysis of pulmonary sound intensity as a non-invasive, more objective, easier and cheaper method to improve diagnostics in unilateral diaphragmatic paralysis.

Research and industry collaboration develops miniature diagnostic platform for respiratory infections such as pneumonia and infectious bronchitis

Featured on the cover of the latest issue of Lab on a Chip

A new strategy in regenerative medicine could promote recovery from damage

Tissue regeneration researchers at IBEC, UB and the UPC have developed an implant that could aid the regeneration of brain tissue, particularly in cases of pre- and postnatal injury.

Researchers from IBEC and ISGlobal’s research centre CRESIB make a major breakthrough in the field of microengineered organs on chips

Scientists from the Institute of Bioengineering of Catalonia (IBEC) and ISGlobal’s research centre CRESIB have designed the first-ever functional 3D splenon capable of reproducing the function of the spleen, which is to filter red blood cells. To do this, they created a microscale platform that reproduces the physical and hydrodynamic properties of the functional unit of the splenic red pulp, the splenon. The device may serve to investigate potential drugs for malaria and other blood disorders. The study reporting the development was published in Lab on a Chip.

Drugs in nanocapsules ‘recognise’ the infected cells of different types of malaria and could help curb resistance

A study by researchers from the Institute for Bioengineering of Catalonia (IBEC) and the Barcelona Centre for International Health Research (CRESIB) demonstrates that an antimalarial drug encapsulated in nanoparticles—chloroquine salts in polyamidoamine polymers—is significantly more effective when delivered in vivo than free (unencapsulated) drugs and may help to curb drug resistance.